
Rheonix is a molecular diagnostics firm working with UB. Richard Montagna (left), senior vice chairman for scientific and scientific affairs at Rheonix, with UB’s Michael Buck, affiliate professor of biochemistry.
By Jessica Szklany
Launch Date: December 15, 2020
BUFFALO, N.Y. — COVID-19 fast diagnostic take a look at kits and their reagents. A next-generation vaccine adjuvant platform. Easy methods to predict dosing of monoclonal antibodies. Air sterilization know-how.
You might not be accustomed to all of those phrases and applied sciences, however should you or a cherished one contracts COVID-19, they might be very important for prevention, prognosis, remedy and restoration. And they’re developed proper right here in Western New York — made doable, partially, by state funding leveraged by the College at Buffalo.
Assist from Governor Andrew M. Cuomo, Empire State Growth and the Division of Science Know-how and Innovation (NYSTAR) has enabled UB to attach its tutorial group with {industry} companions to foster innovation within the life sciences — notably within the areas of recent therapeutics, diagnostics and medical units.
By means of UB’s New York State Middle of Excellence in Bioinformatics & Life Sciences (CBLS), the Middle for Superior Know-how in Massive Information and Well being Sciences (UB CAT) and Buffalo Institute for Genomics and Information Analytics (BIG) — divisions throughout the Office of Business and Entrepreneur Partnerships — UB’s {industry} companions acquire entry to school experience in college and college students, state-of-the-art know-how platforms and funding to speed up the expansion of the life sciences corporations in Western New York. A number of of UB’s {industry} companions have pivoted their analysis and improvement efforts in direction of profitable the battle towards COVID-19.
ZeptoMetrix and Rheonix sort out diagnostics
Advancing COVID-19 testing is a spotlight for ZeptoMetrix, a life sciences firm working to develop new and extremely efficient diagnostic instruments for infectious ailments worldwide. Made doable by the help of BIG, ZeptoMetrix is using know-how on the CBLS that permits the exact quantitation of the quantity of virus formulated into diagnostic take a look at controls that assist to confirm accuracy of COVID-19 take a look at outcomes. With out controls, exams can produce false positives or negatives, inflicting confusion and anguish for sufferers and their households.
To provide reliable controls, ZeptoMetrix scientists inactivate the coronavirus in a specialised lab that permits them to soundly work with extremely infectious brokers after which formulate the handled virus at goal concentrations primarily based upon testing sensitivities. The ensuing non-infectious reagents can then be utilized by hospitals, labs and researchers with out threat of an infection.
“By means of help from BIG and entry to classy laboratory tools situated on the CBLS, we have been capable of higher characterize the focus of inactivated SARS-CoV-2 and thereby create extra exact controls that enormously enhance the testing group’s reliability in conducting COVID-19 molecular exams,” mentioned Shawn Smith, CEO of ZeptoMetrix.

ZeptoMetrix molecular biologist Lauren Morrow masses reagents right into a cartridge utilized in a digital droplet PCR platform with an automatic droplet generator. Picture: Karuna Sharma.
The non-infectious reagents developed by ZeptoMetrix have been utilized by one other UB companion, Rheonix, to advance fast diagnostic COVID-19 testing. Rheonix is a molecular diagnostics firm that produces absolutely automated one-step benchtop testing units and microfluidic assays, utilized in half for the detection of infectious illness. The corporate has a longstanding relationship with UB, together with collaborating with researchers on the CBLS and its Genomics and Bioinformatics Core, and receiving help from UB CAT.
In lower than three months after the pandemic struck the U.S., Rheonix produced a totally automated COVID-19 diagnostic take a look at. With minimal coaching, technicians in accredited scientific laboratories can take and take a look at affected person respiratory samples utilizing the absolutely automated Rheonix workstation, receiving ends in lower than a day versus the a number of days it could actually take to obtain outcomes when sending them out to testing labs.
In April, the Rheonix take a look at obtained the U.S. Meals and Drug Administration’s emergency use authorization (EUA) for COVID-19 testing and is now in use at laboratories in native and regional hospitals and well being networks in New York State and past.
“Speedy prognosis is essential in efforts to regulate the SARS-CoV-2 virus,” mentioned Richard Montagna, senior vice chairman for scientific and scientific affairs at Rheonix. “We at Rheonix are grateful to the individuals on the entrance strains preventing the unfold of the COVID-19 sickness, and are proud to have the ability to help them with a fast, correct and automatic device to help of their efforts.”
POP Biotechnologies pursues a vaccine
Initially of the pandemic, POP Biotechnologies, Inc. (POP BIO), a UB spinout firm situated on the UB Incubator @ Baird, was capable of swiftly transition their particle-based vaccine supply platform to concentrate on addressing the COVID-19 pandemic. The proprietary platform was initially designed to reinforce the efficiency of vaccine antigens for numerous diseases similar to respiratory syncytial virus, HIV and most cancers — work that has been supported by UB CAT funds.
POP BIO developed, and has been testing, a SARS-CoV-2 protein vaccine candidate in partnership with Korean vaccine maker Eubiologics. The outcomes present the system is efficient in preclinical research.
“The underlying know-how can quickly generate immunogenic particles for vaccine functions, and that’s the method we’re pursuing,” defined Jonathan Lovell, co-founder of POP BIO and affiliate professor in UB’s Division of Biomedical Engineering. “We hope to carry it into scientific testing within the close to future.”

POP BIO’s vaccine platform relies upon analysis from the lab of Jonathan Lovell, affiliate professor of biomedical engineering. Credit score: Douglas Levere.
The corporate can also be engaged on a peptide vaccine that doesn’t require freeze storage, permitting for simpler and extra widespread distribution.
In keeping with Lovell, POP BIO’s method has been proven to be notably potent for SARS-CoV-2 vaccine improvement. By means of UB CAT funding, POP BIO will proceed to generate knowledge to additional validate the platform know-how.
As well as, the corporate is receiving a $3 million fairness funding from Eubiologics, with whom it has fashioned a three way partnership, EuPoP Life Sciences, headquartered in Buffalo. POP BIO additionally has energetic analysis collaborations with two main, worldwide pharmaceutical vaccine makers.
Enhanced Pharmacodynamics expedites remedy choices
Whereas a lot COVID-19 analysis is targeting testing and a vaccine, others are engaged on remedy choices to assist save the lives of those that have the virus, together with BIG companion and CBLS tenant, Enhanced Pharmacodynamics (ePD). The large knowledge service supplier is supporting commercialization of a possible remedy for COVID-19, making use of strategies usually used of their work on most cancers drug improvement.
Utilizing a quantitative techniques pharmacology method, ePD creates computational fashions that safely predict how monoclonal antibodies — medication supposed to each stop and deal with present COVID-19 infections — will work together with the human physique. The corporate’s work allows new compounds to be evaluated and to make preliminary dose projections and different drug improvement selections previous to having knowledge in human volunteers from scientific trials.

Scott Van Wart (left) and Donald Mager (proper), each of Enhanced Pharmacodynamics, at UB’s Middle for Computational Analysis. Credit score: Douglas Levere.
A partnership with BIG enabled ePD to buy subtle business software program and grants them entry to computational experience and high-performance supercomputers at UB’s Middle for Computational Analysis (CCR), situated within the CBLS. State-of-the-art computational horsepower by CCR considerably optimizes the corporate’s work. It has additionally benefited from UB interns, a few of which at the moment are ePD workers.
“We make the most of the CCR to run computational machine-learning algorithms, which incorporate numerous in vitro and pre-clinical in vivo knowledge sources, to challenge minimally efficient human dosing regimens to expedite improvement of those novel remedy choices for COVID-19,” mentioned Scott Van Wart, ePD vice chairman and chief scientific officer.
You First Companies stops airborne virus in its tracks
Equally necessary to preventing COVID-19 are prevention strategies similar to environmental techniques designed to take away or destroy pathogens from the air. Buffalo-based firm You First Companies has licensed know-how from UB to develop SteriSpace™, an engineered air sterilization system that makes use of compressive heating and stress to interrupt up and destroy airborne pathogens similar to COVID-19.
SteriSpace generally is a standalone unit for particular person rooms or can scale as much as be built-in right into a constructing’s air dealing with system and customised for various configurations. The know-how will be completely put in to offer clear air for any indoor atmosphere wherein individuals collect the place pathogens are more likely to linger, similar to hospitals and faculties.
Along with licensing know-how from UB, You First Companies is leveraging the CCR on the CBLS, in addition to funding from UB CAT, to simulate and mannequin airflow in indoor areas.
“We extremely worth our long-standing partnership and collaborative hyperlinks with UB. By means of our collaboration with tutorial establishments, now we have gained new views on the most recent applied sciences and developed perception to assist fight present, new and reemerging ailments sooner. The unimaginable high quality of the analysis packages right here at UB has helped make Western New York a number one vacation spot for all times sciences and biotechnology analysis,” mentioned Satish Sharma, govt chairman and chief govt officer of You First Companies Group of Corporations and analysis affiliate professor of urology within the Jacobs College of Medication and Biomedical Sciences at UB.
“Uncontrolled infections can carry miseries, overwhelm the well being care system and negatively influence economies. At You First Companies, we’re dedicated to constantly working to transition fundamental analysis to distinctive and excellent scientific functions when it comes to productiveness, influence and excellence. We’ll proceed to companion with UB to make a major constructive influence on the general financial system of the state and area.”
Partnerships serve the group and past
These are simply a few of the potential life-changing, biomedical applied sciences from UB companions which are remodeling prevention, prognosis and remedy within the international combat towards COVID-19. Continued help of future improvements will assist in cementing Western New York as a hub for all times sciences and positively influence the well being of each group residents and the financial system.
“These university-industry partnerships show the influence of how tutorial and personal organizations locally can be a part of forces to leverage one another’s strengths to seek out options for advanced scientific challenges and processes and finally contribute to innovation and financial progress within the Buffalo Niagara area,” mentioned Christina Orsi, UB affiliate vice chairman for financial improvement.
“For the reason that starting of the pandemic, our campuses went into motion to assist their native communities and the complete state — whether or not it was developing with revolutionary methods to check for COVID-19 or conducting breakthrough analysis to grasp the virus,” mentioned SUNY Chancellor Jim Malatras. “The latest partnerships between College at Buffalo and native organizations in well being care is yet one more instance of SUNY’s energy in working collaboratively with {industry} leaders to unravel for issues and overcome obstacles brought on by COVID-19. Our potential to share assets and experience, as College at Buffalo is doing, will proceed to serve our communities nicely as we work collectively to include the unfold of this lethal virus.”
Empire State Growth Appearing Commissioner, and President and CEO-designate Eric Gertler provides, “The College at Buffalo’s partnerships with {industry} leaders within the combat towards COVID-19 are highlighting the financial and life-saving advantages of New York State’s industry-university collaborations. Governor Cuomo’s strategic investments in Buffalo, and UB entrepreneurship, have laid the groundwork for this scientific analysis that’s serving to communities each battle the pandemic and construct again.”
About UB’s Belongings for Life Sciences
UB’s Center of Excellence in Bioinformatics and Life Sciences (CBLS), Buffalo Institute for Genomics and Data Analytics (BIG), Center for Advanced Technology in Big Data and Health Sciences (UB CAT) and the Biorepository program are strategic belongings for all times sciences innovation and technology-based scientific discovery. Associate collaboration has a confirmed observe report of accelerating progress by connecting corporations with bioinformatics and data resources, together with technical experience, expertise and high-tech genomics and proteomics facilities.
Media Contact Info
Media Relations (College Communications)
330 Crofts Corridor (North Campus)
Buffalo, NY 14260-7015
Tel: 716-645-6969
Fax: 716-645-3765
ub-news@buffalo.edu